Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218142 | 0.98 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL6039740 | 0.93 | — | — | |
| SCHEMBL20230977 | 0.92 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL15199219 | 0.90 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL13214851 | 0.88 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TDP1POLBKDM4E | |
| SCHEMBL13381313 | 0.86 | CHRM5 (0.58) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL24489899 | 0.84 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL21764406 | 0.84 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL13255644 | 0.82 | SIGMAR1 (0.64) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL15199218 | 0.82 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963273-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | claimed |
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| EP-1341760-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-10 | — | — | EP | claimed |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-10 | — | — | US | claimed |
| WO-2002036564-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-10 | — | — | WO | claimed |
| WO-2025024707-A1 | INHIBITORS OF CDK2/4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20230357319-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-11-09 | — | — | US | disclosed |
| EP-4198031-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| CN-104926788-B | Substituted piperidine analog derivative, the pharmaceutical composition containing it and its application in antitumor | 浙江大学 | 2018-08-28 | — | — | CN | disclosed |
| EP-2807482-B1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEV PTE LTD (SG) | 2018-03-14 | — | — | EP | disclosed |
| US-5242919-A | Antiinflammatory agents or hypotensive agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| US-5055474-A | Antihypoxia, hypotensive, antiinflammatory agents; anoxia treatment | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-08 | — | — | US | disclosed |
| EP-0173331-B1 | 2,3-DIHYDRO-1H-INDENE DERIVATIVES, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4895847-A | ANTIHYPOXIC, ANTIINFLAMMATORY, HYPOTENSIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-01-23 | — | — | US | disclosed |
| US-4788130-A | ANTIHYDOXIC, HYPOTENSIVE, ANTIINFLAMMATORY AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-29 | — | — | US | disclosed |
| EP-0173331-A2 | 2,3-Dihydro-1H-indene derivatives, a process for preparing them and pharmaceutical compositions containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
| US-3973981-A | PHTHALOCYANINE DYES, PAINTS, INKS | TOYO INK MANUFACTURING CO., LTD. (JA) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | ALDH1A1 1242/4885SMN1; SMN2 3748/4885TDP1 1927/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | ALDH1A1 1121/4885SMN1; SMN2 4517/4885TDP1 4102/4885 |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | ALDH1A1 1242/4885SMN1; SMN2 3748/4885TDP1 1927/4885 |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, CSNK1A1, MKI67 | ALDH1A1 1477/4885SMN1; SMN2 3484/4885TDP1 1908/4885 |
| US-20230357319-A1 | PROTEASOME INHIBITORS | PSMG3, PSME1, PSMB1 | ALDH1A1 3908/4885SMN1; SMN2 1222/4885TDP1 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.